Why the ResMed (ASX:RMD) share price just hit an all-time high

A confluence of factors are pushing its share price higher.

| More on:
four excited doctors with their hands in the air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc.(ASX: RMD) share price is breaking new records.

At the time of writing, shares in the healthcare company are trading for $35.28 – up 0.54%. At one point, shares reached an intraday and all-time high of $35.44.

The S&P/ASX 200 Index (ASX: XJO) is also having a record day. Presently, the benchmark index is 0.05% higher but reached a high of 7,417.6 points. While the influence of the general market on the ResMed share price could be having an effect, there may be more to the story.

Let's take a closer look.

Healthcare shares are looking fit

Throughout July, ASX healthcare shares, like ResMed, have been surging. Just in the last month, the ResMed share price has jumped 8.1%, Sonic Healthcare Limited (ASX: SHL) improved 8.2% and CSL Limited (ASX: CSL) shares are up 1.5%.

With COVID back in the spotlight, as the delta variant causes a sharp increase in cases across the world, healthcare shares – including ResMed – may be the few to benefit from this strain of the virus.

Experts too have had nothing but positive words to say about the ResMed share price in recent days.

Analysts at Macquarie Group, for example, say ResMed is a growth share for investors to buy right now. Randal Jenneke, head of Australian equities at T Rowe Price Group, says ResMed is a "quality" share for investors.

Jenneke previously said

Over more than two decades of data for the Australian market, high quality had outperformed low quality by 6.7% per annum.

… [quality shares like ResMed are] poised to outperform over the coming year.

As the ResMed share price has just hit a 52-week high, this advice is being borne out – at least for the time being.

Another factor potentially helping ResMed shares – the falling Aussie dollar.

Experts are tipping it to fall below 70 cents against the greenback. For ASX listed companies that predominately do business in the US, this could be a windfall.

ResMed is one of those companies that predominantly trade in the US. In fact, it is a dual listed company with shares on the New York Stock Exchange.

ResMed share price snapshot

Over the past 12 months, the ResMed share price has increased 23.1%. Year-to-date it is up an even greater 28.3%.

ResMed has a market capitalisation of around $51 billion.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man looking happy and excited as he looks at his mobile phone.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on big news

This stock is getting a lot of attention from investors on Wednesday. But why?

Read more »

Four smiling young medics with arms crossed stand outside a hospital.
Healthcare Shares

How much further upside is there for Mesoblast shares after soaring 23% in a month?

Could FDA approval send this healthcare stock towards further gains?

Read more »

woman in lab coat conducting testing representing biotech
Healthcare Shares

Is this soaring ASX 200 healthcare share just getting started?

If its lead therapy gets US approval, the stock can continue to climb.

Read more »

A happy elderly woman smiles and cheers as she looks at good investment news on her laptop.
Broker Notes

Macquarie forecasts this $3.4 billon ASX healthcare share is set surge 33%

Macquarie tips material outperformance from this ASX healthcare share in 2026.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Own CSL shares? Here are the key dates for 2026

It's been a bad year for CSL shares. What's ahead in 2026?

Read more »

A graphic of a pink rocket taking off above an increasing chart.
Healthcare Shares

Guess which ASX 300 healthcare share is rocketing 28% on global expansion news

Investors are piling into the ASX 300 healthcare share on Tuesday. Let’s see why.

Read more »

A man in a business suit scratches his head looking at a graph that started high then dips, then starts to go up again like a rollercoaster.
Healthcare Shares

Is Sigma Healthcare share a healthy buy, after hitting new lows?

The Chemist Warehouse merger and ageing population might boost this stock's appeal.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Telix shares fall despite 'significant milestone'

Let's see what the biotech has announced on Monday.

Read more »